Spark Investment Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Spark Investment Management’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-5,312	Closed	-$44K	–	872
2017 Q3	$44K	Sell	5,312 -12,358	-70%	-$105K	﹤0.01%	695
2017 Q2	$180K	Sell	17,670 -7,030	-28%	-$69.5K	0.01%	672
2017 Q1	$284K	Buy	24,700 +3,700	+18%	+$42K	0.02%	648
2016 Q4	$267K	Buy	21,000 +9,215	+78%	+$146K	0.02%	593
2016 Q3	$215K	Buy	+11,785	New	+$149K	0.02%	652

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

SFS

Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Spark Investment Management's NAVB Position: Q4 2017 in Review

Spark Investment Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2017, closing a stake of 5,312 shares — an estimated $44K sold.

Spark Investment Management first reported a position in NAVB in Q3 2016 and held it in 5 quarters. The position peaked at $284K in Q1 2017. 54 funds tracked by Wall St. Rank hold NAVB as of Q4 2017.

Spark Investment Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2017 after selling out during the quarter.
Spark Investment Management sold 5,312 Navidea Biopharmaceuticals Inc. shares in Q4 2017, an estimated $44K.
Spark Investment Management first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2016 and held it in 5 quarters.
Spark Investment Management's Navidea Biopharmaceuticals Inc. position peaked at $284K in Q1 2017.
54 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2017.

Based on Spark Investment Management's 13F filing for Q4 2017, filed 12 Feb 2018.